HomeCompareIMAB vs MCD

IMAB vs MCD: Dividend Comparison 2026

IMAB yields 69.44% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCD wins by $44.4K in total portfolio value· pulled ahead in Year 8
10 years
IMAB
IMAB
● Live price
69.44%
Share price
$2.88
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$11.77
Full IMAB calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — IMAB vs MCD

📍 MCD pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMABMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMAB + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMAB pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMAB
Annual income on $10K today (after 15% tax)
$5,902.78/yr
After 10yr DRIP, annual income (after tax)
$10.00/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, MCD beats the other by $22,283.54/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMAB + MCD for your $10,000?

IMAB: 50%MCD: 50%
100% MCD50/50100% IMAB
Portfolio after 10yr
$56.4K
Annual income
$13,119.74/yr
Blended yield
23.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

IMAB
Analyst Ratings
5
Buy
Consensus: Buy
Price Target
$8.00
+177.8% upside vs current
Range: $7.00 — $9.00
Altman Z
89.4
Piotroski
3/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMAB buys
0
MCD buys
0
No recent congressional trades found for IMAB or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMABMCD
Forward yield69.44%2.35%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%42.3%
Portfolio after 10y$34.2K$78.5K
Annual income after 10y$11.77$26,227.70
Total dividends collected$8.5K$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$8.00$351.76

Year-by-year: IMAB vs MCD ($10,000, DRIP)

YearIMAB PortfolioIMAB Income/yrMCD PortfolioMCD Income/yrGap
1$14,172$3,472.22$10,815$334.85+$3.4KIMAB
2$17,464$2,299.49$11,826$491.71+$5.6KIMAB
3$20,010$1,324.09$13,123$730.06+$6.9KIMAB
4$22,120$708.96$14,853$1,100.07+$7.3KIMAB
5$24,035$366.22$17,257$1,690.61+$6.8KIMAB
6$25,903$185.94$20,752$2,667.01+$5.2KIMAB
7$27,810$93.64$26,103$4,354.83+$1.7KIMAB
8← crossover$29,804$46.98$34,794$7,437.78$5.0KMCD
9$31,913$23.53$49,926$13,461.60$18.0KMCD
10$34,159$11.77$78,550$26,227.70$44.4KMCD

IMAB vs MCD: Complete Analysis 2026

IMABStock

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Full IMAB Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this IMAB vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMAB vs SCHDIMAB vs JEPIIMAB vs OIMAB vs KOIMAB vs MAINIMAB vs YUMIMAB vs QSRIMAB vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.